U.S. Biologics Patents Could Be Designed To Benefit Developing Worlds
This article was originally published in PharmAsia News
Executive SummaryTreatments for diseases that afflict the developing world could benefit if the U.S. Congress makes the right moves in how generic versions of biotechnology drugs are regulated, according to a consultant to follow-on biologics companies. Ian Spatz of the Rock Creek Policy Group, writing in the journal Health Affairs, said that in setting the number of years of patent protection for biotech drugs or devices, Congress could provide an extension for companies that show their products are particularly suitable for use in the developing world. In some cases, the drugs or diagnostics could be for treating diseases such as HIV, taking into account the lack of proper storage capability in some developing countries. (Click here for more
You may also be interested in...
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
Several newly repurposed drugs, including a Bayer antimalarial, have shown potential benefits against the new coronavirus, promoting China to add several to its latest revised treatment guidelines.
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.